Proteinuria due to suboptimal hydration with high-dose methotrexate therapy

Area of Science:

• Pediatric Oncology
• Nephrology
• Pharmacology

Background:

• High-dose methotrexate (HDMTX) is a critical chemotherapy agent for pediatric malignancies.
• Renal damage, manifesting as proteinuria, is a significant complication of HDMTX therapy.
• Previous protocols for managing HDMTX-induced nephrotoxicity were suboptimal.

Purpose of the Study:

• To investigate the incidence of proteinuria following HDMTX administration in pediatric cancer patients.
• To evaluate the efficacy of a modified hydration and urinary alkalization protocol in preventing HDMTX-induced renal damage.

Main Methods:

• Retrospective analysis of 52 HDMTX courses in 24 children (1989-1990) with a standard hydration/alkalization protocol.
• Prospective evaluation of 24 children (1991-1992) with a modified intensive intravenous prehydration and posthydration protocol including sodium bicarbonate.
• Urine protein levels were measured pre-treatment, and on days 1 and 2 post-infusion.

Main Results:

• The initial protocol showed a significant increase in proteinuria (mean 0.38 g/m2 on day 1, 0.39 g/m2 on day 2) in 54% of patients.
• The modified protocol resulted in significantly lower mean proteinuria levels (0.05 g/m2 on day 1, 0.08 g/m2 on day 2), all within normal ranges.
• Statistical analysis confirmed a significant difference between the two protocols (P < 0.05).

Conclusions:

• Standard hydration and alkalization are insufficient to prevent HDMTX-induced proteinuria in children.
• An intensive intravenous hydration and urinary alkalization regimen effectively mitigates proteinuria associated with HDMTX therapy.
• This modified approach is crucial for preventing renal complications in pediatric patients undergoing HDMTX treatment.